Vivanza Biosciences Ltd Upgraded to Sell on Improved Valuation and Financial Trends

Valuation Improvement Drives Upgrade

The primary catalyst for the rating upgrade is a significant enhancement in Vivanza Biosciences’ valuation profile. The company’s valuation grade shifted from 'Risky' to 'Attractive', signalling a more favourable price point relative to its earnings and asset base. Key valuation ratios underpinning this change include a Price-to-Earnings (PE) ratio of -57.33, reflecting losses but also a depressed share price that discounts future growth potential. The Price-to-Book (P/B) ratio stands at 1.87, indicating the stock is trading below twice its book value, which is reasonable for a pharmaceutical micro-cap.

Enterprise Value (EV) multiples also support the upgrade, with EV to EBIT and EV to EBITDA ratios at -18.14, negative due to recent losses but suggesting the market is pricing in recovery potential. The EV to Capital Employed ratio is a modest 1.28, further reinforcing the stock’s attractive valuation relative to its capital base. Compared to peers such as Jindal Photo (PE 9.75, EV/EBITDA 129.34) and Arfin India (PE 146.64, EV/EBITDA 38.16), Vivanza’s valuation appears compelling despite its financial challenges.

Quality Parameters Remain Weak

Despite the valuation improvement, Vivanza Biosciences continues to exhibit weak quality metrics. The company’s Return on Capital Employed (ROCE) is negative at -0.64%, and Return on Equity (ROE) is also negative at -6.72% for the latest period, indicating poor profitability and inefficient use of shareholder funds. Over the last five years, the company has recorded a -4.85% compound annual growth rate (CAGR) in operating profits, highlighting persistent operational challenges.

Additionally, the company’s ability to service debt remains limited, with a high Debt to EBITDA ratio of 5.05 times, signalling elevated financial risk. The average ROE over recent years is a modest 9.70%, underscoring low returns generated per unit of equity invested. These factors contribute to the company’s overall Mojo Grade remaining at 34.0, classified as a Sell, albeit improved from the previous Strong Sell rating.

Financial Trend: Mixed Signals Amidst Positive Quarterly Performance

Vivanza Biosciences reported positive financial results for Q3 FY25-26, with net sales for the latest six months rising to ₹100.61 crores and profit after tax (PAT) improving to ₹0.76 crores. However, these gains are tempered by longer-term underperformance. The stock has delivered a negative return of -7.33% over the past year, underperforming the BSE500 benchmark, which gained 8.52% in the same period.

Over three and five years, the stock’s returns have been deeply negative at -84.92% and -88.06% respectively, contrasting sharply with the Sensex’s robust gains of 36.73% and 60.30% over the same durations. This persistent underperformance reflects structural challenges in the company’s business model and competitive positioning.

Profitability trends also remain subdued, with a 7% decline in profits over the past year despite the recent quarterly improvement. The company’s operating profit growth has been negative over the last five years, signalling ongoing difficulties in scaling earnings sustainably.

Technicals Show Signs of Recovery

Technically, Vivanza Biosciences has demonstrated some positive momentum, with the stock price rising 4.88% on 16 February 2026 to ₹2.15 from the previous close of ₹2.05. The stock’s 52-week trading range is ₹1.90 to ₹2.94, indicating limited volatility but a potential base for recovery. The recent uptick contrasts with the broader market’s modest decline of -1.14% over the past week, suggesting relative strength in the short term.

Market capitalisation remains modest, with a Market Cap Grade of 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector. Majority shareholding is held by non-institutional investors, which may contribute to lower liquidity and higher volatility.

Contextualising the Upgrade Within Sector and Market Trends

Within the Pharmaceuticals & Biotechnology sector, Vivanza Biosciences’ upgrade to Sell from Strong Sell is a cautious step reflecting improved valuation and technicals but persistent fundamental weaknesses. The sector has witnessed mixed performances, with many peers trading at higher valuations but demonstrating stronger profitability and growth metrics.

Vivanza’s attractive valuation multiples relative to peers such as Antony Waste Handling (PE 23.93, EV/EBITDA 9.11) and Signpost India (PE 25.85, EV/EBITDA 12.33) suggest the market is pricing in recovery potential despite the company’s negative returns and profitability challenges. Investors should weigh the improved technical momentum and valuation against the company’s weak financial trends and quality scores before considering exposure.

Outlook and Investor Considerations

While the upgrade to Sell indicates a less pessimistic stance, Vivanza Biosciences remains a high-risk investment given its negative returns over multiple time horizons and weak profitability metrics. The company’s recent quarterly sales and profit improvements offer some hope for stabilisation, but the long-term trend of declining operating profits and high debt servicing risk remain concerns.

Investors should monitor upcoming quarterly results closely for sustained improvement in profitability and cash flow generation. The stock’s attractive valuation and recent technical strength may appeal to value-oriented investors with a high risk tolerance, but caution is warranted given the company’s structural challenges and sector volatility.

Summary of Ratings and Scores

As of 13 February 2026, Vivanza Biosciences holds a Mojo Score of 34.0 with a Mojo Grade of Sell, upgraded from Strong Sell. The Market Cap Grade is 4, reflecting its micro-cap status. Valuation metrics have improved markedly, shifting from Risky to Attractive, while quality and financial trend parameters remain weak. Technical indicators have shown recent positive momentum, contributing to the rating upgrade.

Overall, the upgrade reflects a nuanced view balancing improved valuation and technicals against persistent fundamental weaknesses, signalling cautious optimism but continued risk for investors.

Unlock special upgrade rates for a limited period. Start Saving Now →